Orionis Biosciences

Thanks CNBC Overtime, Jon Fortt, and Morgan L Brennan for having me on today. Highlights that I shared live: Apple has wrapped AI into something that is really a product Apple is always good at making products out of technology. Apple continues to have market power. I’m looking forward to seeing how Apple delivers! Catch more here: https://lnkd.in/dEZbTfsE AND if you're interested in AI then you should learn more about these Build Collective portfolio companies and the truly amazing work they are doing: Orionis Biosciences, Smartex.ai, Greyparrot, Nabla, Meeno #BUILD #BuildBook #technology #AI #innovation

🏆 Thrilled to announce that our collaboration with Orionis Biosciences has been honored as the Alliance of the Year 2023 by In Vivo! This recognition underscores our dedication to forging groundbreaking partnerships, exemplified by our work with partners like Orionis Biosciences to discover molecular glues. Excited to propel the boundaries of science forward in this transformative space! #Innovation #Partnership https://lnkd.in/drfkNrse

The Genentech/Orionis deal was selected as a finalist in In Vivo's "Deals of the Year" contest - Please feel free to vote for us 😊 in the "Top Alliances of 2023" category 🤗 https://lnkd.in/eYwUEdwS

Two important company announcements today! 1: New milestone reached with our first-in-class, targeted interferon A-Kine®, ORB-011. First cancer patient dosed in a Phase 1 immunotherapy clinical trial for advanced solid tumors. 2: Tony Fadell, Founder and Principal at Build Collective, joins Orionis Board of Directors. Learn more here: https://lnkd.in/gegFNATk #immunotherapy #cancerresearch #clinicaltrials #solidtumors

Thank you Tony Fadell for your support. We’re very excited to have you join the board and help us navigate the future! And a big thank you also to Matias de Tezanos for having been an incredibly supportive board member over the past years, and for continuing to be part of the journey. Exciting times ahead!

Two important company announcements today! 1: New milestone reached with our first-in-class, targeted interferon A-Kine®, ORB-011. First cancer patient dosed in a Phase 1 immunotherapy clinical trial for advanced solid tumors. 2: Tony Fadell, Founder and Principal at Build Collective, joins Orionis Board of Directors. Learn more here: https://lnkd.in/gegFNATk #immunotherapy #cancerresearch #clinicaltrials #solidtumors